Top Story Today
The Cancer Treatment That Wasn't Supposed to Work Just Got Approved
For over a decade, CAR-T cell therapy dominated blood cancers but couldn't crack solid tumors, the dense masses responsible for most cancer deaths. China just changed that. Its drug regulator approved satricabtagene autoleucel, the world's first CAR-T for a solid tumor (advanced stomach cancer), developed by Shanghai-based CARsgen Therapeutics. The survival gains are modest: about 7.9 months versus 5.5 months compared to standard treatment. But the approval validates a pathway the entire field had written off. China now hosts roughly half of all CAR-T clinical trials globally, while the U.S. has zero solid-tumor CAR-T programs in Phase 3.
Why it matters: This cracks open a barrier that has defined the limits of cell therapy for a generation. For investors, solid-tumor CAR-T just moved from theoretical to commercial, and the fact that China got there first adds a geopolitical dimension to the global cell therapy race.
Read more →Regulatory Shockwaves
Europe Pulls the Plug on an Amgen Drug Over Faked Trial Data
Europe's drug regulator recommended revoking Amgen's Tavneos (avacopan), a rare autoimmune vasculitis treatment, after concluding the pivotal trial data were "incorrect and misleading." This is a rare outright revocation in EU history, and notably one driven by data integrity rather than safety signals discovered after approval. The FDA flagged the same concerns back in January 2026. The message to every biotech running trials: your data will be scrutinized long after approval.
Read more →Sobi's Gout Drug Aced Its Trials. The FDA Rejected It Anyway.
The FDA rejected Sobi's gout therapy NASP with zero concerns about efficacy or safety. The problem was entirely manufacturing: inadequate quality data and deficiencies at contract production facilities. It's part of a pattern where roughly 70-74% of recent FDA rejections involve manufacturing issues, not clinical failures. The factory floor, not the clinic, has become biotech's biggest bottleneck.
Read more →CDC Had Proof COVID Vaccines Work. Someone Buried the Study.
A CDC study showing COVID vaccines cut hospitalizations by 55% was cleared for publication, scheduled for release, then personally blocked by acting director Jay Bhattacharya. The paper eventually appeared in JAMA Network Open months later, surviving rigorous independent peer review. Former CDC officials called it censorship of taxpayer-funded science.
Read more →The FDA Under Stress
The FDA Fired 3,500 People. Now It's Hiring 2,200 Back.
After slashing roughly 20% of its workforce, the FDA is scrambling to refill 2,200 positions. About 600 are in the pipeline. But even fully staffed, the agency ends up net negative by 1,300 people. The oncology review team alone shrank from about 100 to around 50. Drug reviews held up in 2025, barely, but early-stage company meetings and biologics timelines are already slipping.
Read more →Seven Companies Just Got a Backstage Pass to FDA Drug Approval
The FDA picked Eli Lilly, Regeneron, and five others for its new PreCheck pilot, which lets the agency review drug factories while they're still being built. Only new U.S.-based facilities qualify, making this equal parts regulatory reform and domestic manufacturing play.
Read more →The FDA's Gene Therapy Office Just Lost Its Third Senior Leader
The acting director of the FDA's gene therapy review office stepped down, following two other senior officials placed on leave and a string of high-profile departures from CBER leadership. The office has 2,500+ active applications on file. Rejection rates for cell and gene therapies have climbed to 38% over recent months, up from 18% during 2020-2024.
Read more →Deals, Trials, and Geopolitics
Congress Opens National Security Probe into Merck and AbbVie's China Trials
The House Select Committee on China is investigating whether Merck's 224 clinical studies in China (at least 40 at military-linked hospitals) and AbbVie's 100+ studies exposed U.S. biotech IP to the Chinese military. No laws were broken, but proposed legislation could ban the FDA from accepting China-generated trial data entirely by 2028.
Read more →Biogen Bets $850M on China While Everyone Else Pulls Back
Biogen paid $100 million upfront (up to $850M total) for Greater China rights to felzartamab, an immune disease antibody, from TJ Biopharma. Shares rose modestly after the announcement. China's autoimmune market is projected to grow rapidly, math that apparently outweighs geopolitical risk.
Read more →Europe Approves the World's First Flu-COVID Combo Vaccine
Moderna's mCOMBRIAX, the first vaccine combining flu and COVID protection in a single shot, won EU approval for adults 50 and older. It outperformed both standalone vaccines in head-to-head trials. With European COVID booster uptake cratering to 8.7% among seniors, one-shot convenience could meaningfully move the needle on protection.
Read more →Moderna's Bird Flu Vaccine Enters Phase 3 Testing
The first mRNA bird flu vaccine to reach late-stage testing showed 97.8% of participants hitting protective antibody levels after two doses in earlier-stage trials. The Phase 3 trial is enrolling 4,000 adults across the U.S. and U.K., with a full FDA application targeted for Q3 2026. With 71 confirmed U.S. human H5N1 cases, the timing is urgent.
Read more →